These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

108 related articles for article (PubMed ID: 19069489)

  • 1. [Trospium chloride in combined treatment of females with genital prolapse and overactive urinary bladder].
    Shkol'nikov Me; Mazo EB; Krivoborodov GG; Dobrokhotova IuE; Kaĭfadzhan MM; Fandeeva LV; Nurullin RF; Zhdanova MS
    Urologiia; 2008; (5):16-9. PubMed ID: 19069489
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Experience with application of trospium chloride in patients with neurogenic detrusor overactivity].
    Shvarts PG; Kadykov AS; Shvedkov VV; Timerbaeva SL; Polevaia EV; Mulach AN
    Urologiia; 2009; (5):24-9. PubMed ID: 20213911
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Extended-release trospium chloride improves quality of life in overactive bladder.
    Dmochowski RR; Rosenberg MT; Zinner NR; Staskin DR; Sand PK
    Value Health; 2010; 13(2):251-7. PubMed ID: 19818062
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Once daily trospium chloride is effective and well tolerated for the treatment of overactive bladder: results from a multicenter phase III trial.
    Staskin D; Sand P; Zinner N; Dmochowski R;
    J Urol; 2007 Sep; 178(3 Pt 1):978-83; discussion 983-4. PubMed ID: 17632131
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Once-daily administration of trospium chloride extended release provides 24-hr coverage of nocturnal and diurnal symptoms of overactive bladder: an integrated analysis of two phase III trials.
    Ginsberg DA; Oefelein MG; Ellsworth PI
    Neurourol Urodyn; 2011 Apr; 30(4):563-7. PubMed ID: 21268101
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Transcutaneous posterior tibial nerve electrostimulation with low dose trospium chloride: Could it be used as a second line treatment of overactive bladder in females.
    Abulseoud A; Moussa A; Abdelfattah G; Ibrahim I; Saba E; Hassouna M
    Neurourol Urodyn; 2018 Feb; 37(2):842-848. PubMed ID: 28792105
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Baseline incontinence severity is predictive of the percentage of patients continent after receiving once-daily trospium chloride extended release.
    Staskin DR; Cardozo L
    Int J Clin Pract; 2009 Jun; 63(6):973-6. PubMed ID: 19459997
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety and efficacy of once-daily trospium chloride extended-release in male patients with overactive bladder.
    MacDiarmid SA; Ellsworth PI; Ginsberg DA; Oefelein MG; Sussman DO
    Urology; 2011 Jan; 77(1):24-9. PubMed ID: 20970833
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Overactive bladder as a mask of chronic prostatitis].
    Kul'chavenia EV; Brizhatiuk EV; Breusov AA
    Urologiia; 2012; (6):43-4, 46. PubMed ID: 23379238
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Trospium chloride once-daily extended release is efficacious and tolerated in elderly subjects (aged ≥ 75 years) with overactive bladder syndrome.
    Sand PK; Johnson Ii TM; Rovner ES; Ellsworth PI; Oefelein MG; Staskin DR
    BJU Int; 2011 Feb; 107(4):612-20. PubMed ID: 20707790
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of intravaginal electrical stimulation and trospium hydrochloride in women with overactive bladder syndrome: a randomized controlled study.
    Ozdedeli S; Karapolat H; Akkoc Y
    Clin Rehabil; 2010 Apr; 24(4):342-51. PubMed ID: 20212061
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Trospium chloride in the treatment of idiopathic and neurogenic detrusor overactivity].
    Mazo EB; Krivoborodov GG; Shkol'nikov ME; Babanina GA; Kozyrev SV; Korshunov ES
    Urologiia; 2005; (4):56-9. PubMed ID: 16158750
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Trospium chloride once daily for overactive bladder syndrome: results of a multicenter observational study].
    Notz HJ; Hautumm B; Werdier D; Groves R; Odenthal KP
    Urologe A; 2013 Jan; 52(1):65-70. PubMed ID: 23052979
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Trospium 60 mg once daily (QD) for overactive bladder syndrome: results from a placebo-controlled interventional study.
    Dmochowski RR; Sand PK; Zinner NR; Staskin DR
    Urology; 2008 Mar; 71(3):449-54. PubMed ID: 18342185
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Obesity is associated with a more severe overactive bladder disease state that is effectively treated with once-daily administration of trospium chloride extended release.
    Chancellor MB; Oefelein MG; Vasavada S
    Neurourol Urodyn; 2010 Apr; 29(4):551-4. PubMed ID: 19634167
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Time to onset of improvement in symptoms of overactive bladder using antimuscarinic treatment.
    Rudy D; Cline K; Harris R; Goldberg K; Dmochowski R
    BJU Int; 2006 Mar; 97(3):540-6. PubMed ID: 16469022
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Trospium chloride and oxybutynin hydrochloride in a german study of adults with urinary urge incontinence: results of a 12-week, multicenter, randomized, double-blind, parallel-group, flexible-dose noninferiority trial.
    Zellner M; Madersbacher H; Palmtag H; Stöhrer M; Bödeker RH;
    Clin Ther; 2009 Nov; 31(11):2519-39. PubMed ID: 20109997
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [High-dose trospium chloride in therapy of detrusor hyperreflexia].
    Madersbacher H; Stöhrer M; Richter R; Giannetti BM; Mürtz G
    Urologe A; 1991 Jul; 30(4):260-3. PubMed ID: 1926674
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The overactive bladder-symptom composite score: a composite symptom score of toilet voids, urgency severity and urge urinary incontinence in patients with overactive bladder.
    Zinner N; Harnett M; Sabounjian L; Sandage B; Dmochowski R; Staskin D
    J Urol; 2005 May; 173(5):1639-43. PubMed ID: 15821526
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Once-daily trospium chloride 60 mg extended-release provides effective, long-term relief of overactive bladder syndrome symptoms.
    Zinner NR; Dmochowski RR; Staskin DR; Siami PF; Sand PK; Oefelein MG
    Neurourol Urodyn; 2011 Sep; 30(7):1214-9. PubMed ID: 21462240
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.